Meeting
2016 ASCO Annual Meeting
The addition of adjuvant chemotherapy to radiation in high risk endometrial cancer: Survival outcomes and patterns of care.
Authors
Dustin Boothe
Department of Radiation Oncology, Huntsman Cancer Hospital; University of Utah School of Medicine, Salt Lake City, UT
Dustin Boothe , Ned Williams , Bismarck Odei , Matt Poppe , Theresa Louise Werner , Gita Suneja , David K. Gaffney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5587)
DOI
10.1200/JCO.2016.34.15_suppl.5587
Abstract #
5587
Poster Bd #
410
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.
First Author: Toon Van Gorp
Poster
2021 Genitourinary Cancers Symposium
High-risk nonmetastatic prostate cancer in the elderly: Does adjuvant chemotherapy affect survival?
First Author: Komal Akhtar
Poster
2019 ASCO Annual Meeting
Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results.
First Author: Giuseppe Lamberti
Poster
2019 Genitourinary Cancers Symposium
Overall survival outcomes with the use of adjuvant chemotherapy, radiation therapy and hormone therapy in high-risk, very-high-risk and node-positive prostate cancer post radical prostatectomy: A NCDB analysis.
First Author: Alina Basnet